{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:54:48Z","timestamp":1778594088389,"version":"3.51.4"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110033","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:04:01Z","timestamp":1593176641000},"page":"110033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms"],"prefix":"10.1016","volume":"144","author":[{"given":"Mahmoud A.","family":"El-Ghiaty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M.","family":"Shoieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman O.S.","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110033_b0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"10228","key":"10.1016\/j.mehy.2020.110033_b0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30557-2","article-title":"SARS-CoV-2 is an appropriate name for the new coronavirus","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0015","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"issue":"7798","key":"10.1016\/j.mehy.2020.110033_b0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2020.110033_b0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in wuhan, china, of novel coronavirus\u2013infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"issue":"10223","key":"10.1016\/j.mehy.2020.110033_b0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.mehy.2020.110033_b0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110033_b0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00405-020-05965-1","article-title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study","author":"Lechien","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30110-7","article-title":"Respiratory support for patients with COVID-19 infection","volume":"8","author":"Namendys-Silva","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.mehy.2020.110033_b0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.mehy.2020.110033_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.mehy.2020.110033_b0060","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1128\/JVI.00289-09","article-title":"The first virally encoded cytochrome p450","volume":"83","author":"Lamb","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome p450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.mehy.2020.110033_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","article-title":"Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts","volume":"43","author":"Ding","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9340","key":"10.1016\/j.mehy.2020.110033_b0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(02)11203-7","article-title":"Clinical importance of the cytochromes P450","volume":"360","author":"Nebert","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0090","first-page":"263","article-title":"Basic review of the cytochrome p450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol."},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey","year":"2014","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jfda.2018.11.005","article-title":"The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders","volume":"27","author":"Wu","year":"2019","journal-title":"J Food Drug Anal"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"issue":"4 Pt 1","key":"10.1016\/j.mehy.2020.110033_b0115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840220420","article-title":"Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture","volume":"22","author":"Muntane-Relat","year":"1995","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.mehy.2020.110033_b0120","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0125","first-page":"367","article-title":"Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes","volume":"24","author":"Tapner","year":"1996","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.mehy.2020.110033_b0130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0006-2952(98)00178-6","article-title":"Comparative effects of cytokines on constitutive and inducible expression of the gene encoding for the cytochrome P450 3A6 isoenzyme in cultured rabbit hepatocytes: consequences on progesterone 6beta-hydroxylation","volume":"56","author":"Calleja","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/taap.1996.0077","article-title":"Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes","volume":"137","author":"Monshouwer","year":"1996","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0026-895X(25)13247-1","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/dmd.114.059246","article-title":"HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes","volume":"43","author":"Rubin","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0090-9556(24)15152-5","article-title":"Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver","volume":"28","author":"Pan","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0006-2952(93)90078-B","article-title":"Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo. Independence from the hypothalamo-pituitary axis","volume":"45","author":"Morgan","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","article-title":"Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure","volume":"8","author":"Frye","year":"2002","journal-title":"J Card Fail."},{"issue":"1\u20132","key":"10.1016\/j.mehy.2020.110033_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0006-8993(99)01261-5","article-title":"Modulation of cytochrome P450 by inflammation in astrocytes","volume":"827","author":"Nicholson","year":"1999","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0170","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO;2-L","article-title":"Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells","volume":"90","author":"Bertilsson","year":"2001","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.mehy.2020.110033_b0175","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0006-2952(01)00859-0","article-title":"Role of cytokines in the lipopolysaccharide-evoked depression of cytochrome P450 in the brain and liver","volume":"62","author":"Nicholson","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1476-5381.2008.00050.x","article-title":"The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC","volume":"156","author":"Liptrott","year":"2009","journal-title":"Br J Pharmacol."},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00755608","article-title":"Repression of cytochrome P450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes","volume":"9","author":"Parmentier","year":"1993","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/abbi.2000.1772","article-title":"Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site","volume":"377","author":"Iber","year":"2000","journal-title":"Arch Biochem Biophys"},{"issue":"7","key":"10.1016\/j.mehy.2020.110033_b0195","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2174\/138920012802138642","article-title":"Effects of interleukin 1beta (IL-1beta) and IL-1beta\/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture","volume":"13","author":"Dickmann","year":"2012","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0016-5085(95)90285-6","article-title":"Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha","volume":"109","author":"Nadin","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0205","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0022-3565(24)36605-4","article-title":"Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes","volume":"281","author":"Donato","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.mehy.2020.110033_b0210","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjp.0703486","article-title":"Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines","volume":"130","author":"Bleau","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0215","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/0016-5085(95)90648-7","article-title":"The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes","volume":"109","author":"Tinel","year":"1995","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.mehy.2020.110033_b0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1067\/mcp.2000.103860","article-title":"In vivo effects of interleukin-10 on human cytochrome P450 activity","volume":"67","author":"Gorski","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0230","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.bjp.0701232","article-title":"Down-regulation of the hepatic cytochrome P450 by an acute inflammatory reaction: implication of mediators in human and animal serum and in the liver","volume":"121","author":"El-Kadi","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.mehy.2020.110033_b0235","first-page":"1007","article-title":"Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction","volume":"29","author":"Bleau","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0240","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-291X(91)90998-M","article-title":"Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes","volume":"178","author":"Williams","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0006-2952(92)90047-M","article-title":"Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat","volume":"44","author":"Chen","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0250","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(92)90684-D","article-title":"Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells","volume":"184","author":"Fukuda","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0255","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-895X(25)09656-7","article-title":"Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin","volume":"36","author":"Morgan","year":"1989","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0260","first-page":"475","article-title":"Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver","volume":"1219","author":"Morgan","year":"1994","journal-title":"BBA"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0265","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0026-895X(25)08588-8","volume":"47","author":"Chen","year":"1995","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/jhep.2000.8532","article-title":"Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent","volume":"32","author":"Siewert","year":"2000","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.mehy.2020.110033_b0275","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1124\/dmd.32.7.707","article-title":"Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver","volume":"32","author":"Ashino","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0280","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1124\/jpet.110.171488","article-title":"Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice","volume":"335","author":"Nyagode","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.mehy.2020.110033_b0285","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/107999001753238060","article-title":"Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute-phase response","volume":"21","author":"Warren","year":"2001","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0290","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1124\/mol.64.1.42","article-title":"Transgenic mouse models of human CYP3A4 gene regulation","volume":"64","author":"Robertson","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"24","key":"10.1016\/j.mehy.2020.110033_b0295","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1158\/1078-0432.CCR-06-0023","article-title":"Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer","volume":"12","author":"Charles","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bjc.6604101","article-title":"Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies","volume":"98","author":"Sharma","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.mehy.2020.110033_b0305","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-013-1042-3","article-title":"Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling","volume":"30","author":"Kacevska","year":"2013","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0310","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","article-title":"Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4","volume":"30","author":"Mimura","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"10.1016\/j.mehy.2020.110033_b0315","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.mehy.2020.110033_b0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/PL00000260","article-title":"Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes","volume":"50","author":"Ruminy","year":"2001","journal-title":"Inflamm Res"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0325","first-page":"207","article-title":"Regulation of cytochrome p450 by inflammatory mediators: why and how?","volume":"29","author":"Morgan","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"10.1016\/j.mehy.2020.110033_b0330","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1038\/sj.onc.1209943","article-title":"NF-kappaB and the immune response","volume":"25","author":"Hayden","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0335","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/138920009787522151","article-title":"Role of NF-kappaB in the regulation of cytochrome P450 enzymes","volume":"10","author":"Zordoky","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"43","key":"10.1016\/j.mehy.2020.110033_b0340","doi-asserted-by":"crossref","first-page":"39638","DOI":"10.1074\/jbc.M106286200","article-title":"Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide","volume":"276","author":"Ke","year":"2001","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2020.110033_b0345","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0009-2797(02)00068-6","article-title":"Ah receptor and NF-kappaB interactions: mechanisms and physiological implications","volume":"141","author":"Tian","year":"2002","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/dmd.105.006528","article-title":"Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6","volume":"34","author":"Kourylko","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"29","key":"10.1016\/j.mehy.2020.110033_b0355","doi-asserted-by":"crossref","first-page":"47296","DOI":"10.18632\/oncotarget.17624","article-title":"Inhibition of nuclear factor-kappaB signal by pyrrolidine dithiocarbamate alleviates lipopolysaccharide-induced acute lung injury","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.mehy.2020.110033_b0360","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J Clin Invest"},{"issue":"26","key":"10.1016\/j.mehy.2020.110033_b0365","doi-asserted-by":"crossref","first-page":"17882","DOI":"10.1074\/jbc.M601302200","article-title":"Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents","volume":"281","author":"Gu","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0370","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2010.06.003","article-title":"Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes","volume":"197","author":"Yang","year":"2010","journal-title":"Toxicol Lett"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0375","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ejca.2006.01.005","article-title":"Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?","volume":"42","author":"Assenat","year":"2006","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0380","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1471-4159.2004.02449.x","article-title":"A novel lipopolysaccharide-modulated Jun binding repressor in intron 2 of CYP2E1","volume":"89","author":"Tindberg","year":"2004","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0385","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10224","key":"10.1016\/j.mehy.2020.110033_b0390","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"01","key":"10.1016\/j.mehy.2020.110033_b0395","article-title":"The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes","volume":"2020","author":"Zhang","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0400","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"issue":"10229","key":"10.1016\/j.mehy.2020.110033_b0405","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0410","doi-asserted-by":"crossref","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV- 2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0415","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10230","key":"10.1016\/j.mehy.2020.110033_b0420","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0425","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"issue":"10229","key":"10.1016\/j.mehy.2020.110033_b0430","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110033_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"6490","key":"10.1016\/j.mehy.2020.110033_b0440","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.mehy.2020.110033_b0445","doi-asserted-by":"crossref","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020:202005615. 10.1073\/pnas.2005615117.","DOI":"10.1073\/pnas.2005615117"},{"key":"10.1016\/j.mehy.2020.110033_b0450","unstructured":"Guo C, Li B, Ma H, et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. bioRxiv. 2020:2020.04.08.029769. 10.1101\/2020.04.08.029769."},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0455","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/00498250110112006","article-title":"Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices","volume":"32","author":"De Kanter","year":"2002","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1389200043489054","article-title":"The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes","volume":"5","author":"Elbekai","year":"2004","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389200043335531","article-title":"Cytochrome P450 and liver diseases","volume":"5","author":"Villeneuve","year":"2004","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(98)90017-0","article-title":"Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6","volume":"64","author":"Adedoyin","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0475","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450\u2013mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.110033_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(20)30084-4","article-title":"COVID-19 and the liver: little cause for concern","author":"Bangash","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.mehy.2020.110033_b0485","unstructured":"Rismanbaf A, Zarei S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. Archives of academic emergency medicine. 2020;8(1):e17-e."},{"key":"10.1016\/j.mehy.2020.110033_b0490","article-title":"Clinical characteristics of 138 hospitalized patients with novel coronavirus-infected pneumonia in Wuhan, China","volume":"2020","author":"Wang","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mehy.2020.110033_b0495","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.mehy.2020.110033_b0500","article-title":"Coronavirus disease (COVID-19) and prevalence of chronic liver disease: A meta-analysis","volume":"2020","author":"Mantovani","year":"2019","journal-title":"Liver International."},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0505","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.103179","article-title":"Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients","volume":"20","author":"Omrani-Nava","year":"2020","journal-title":"Hepat Mon."},{"key":"10.1016\/j.mehy.2020.110033_b0510","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14477","article-title":"Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis","author":"Paliogiannis","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0515","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/hep.20111","article-title":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases","volume":"39","author":"Chau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2020.110033_b0520","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.02.054","article-title":"COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission","author":"Gu","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0525","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/his.13379","article-title":"Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study","volume":"72","author":"Alsaad","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.mehy.2020.110033_b0530","first-page":"E002","article-title":"Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi","volume":"28","author":"Guan","year":"2020","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.mehy.2020.110033_b0535","doi-asserted-by":"crossref","unstructured":"Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. 2020:2020.02.03.931766. 10.1101\/2020.02.03.931766.","DOI":"10.1101\/2020.02.03.931766"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0540","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: management and challenges","volume":"5","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0545","doi-asserted-by":"crossref","DOI":"10.14218\/JCTH.2020.00018","article-title":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies","volume":"8","author":"Feng","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.mehy.2020.110033_b0550","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14470","article-title":"COVID-19 and liver disease","author":"Sun","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0555","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2353\/ajpath.2006.051296","article-title":"Systemic viral infections and collateral damage in the liver","volume":"168","author":"Adams","year":"2006","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0560","doi-asserted-by":"crossref","DOI":"10.2353\/ajpath.2006.050875","article-title":"Kupffer cell-dependent hepatitis occurs during influenza infection","volume":"168","author":"Polakos","year":"2006","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0565","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1111\/j.1750-2659.2011.00287.x","article-title":"Liver involvement during influenza infection: perspective on the 2009 influenza pandemic","volume":"6","author":"Papic","year":"2012","journal-title":"Influenza Other Respi Viruses"},{"issue":"10","key":"10.1016\/j.mehy.2020.110033_b0570","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-018-0650-9","article-title":"Complex drug-drug-gene-disease interactions involving cytochromes P450: systematic review of published case reports and clinical perspectives","volume":"57","author":"Storelli","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0575","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pds.1197","article-title":"Trends in new drug interactions for pharmaceutical products in Japan","volume":"15","author":"Yoshida","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0580","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1060028014526701","article-title":"Infection and inflammation leading to clozapine toxicity and intensive care: a case series","volume":"48","author":"Leung","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0585","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","article-title":"Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis","volume":"50","author":"Mayo","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.mehy.2020.110033_b0590","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00228-013-1525-5","article-title":"Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate","volume":"69","author":"Morcos","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0595","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","article-title":"Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity","volume":"72","author":"Sanaee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0600","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","article-title":"Variability in drug metabolizing enzyme activity in HIV-infected patients","volume":"66","author":"Jones","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110033_b0605","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1542\/peds.69.4.476","article-title":"Altered theophylline clearance during an influenza B outbreak","volume":"69","author":"Kraemer","year":"1982","journal-title":"Pediatrics"},{"issue":"15","key":"10.1016\/j.mehy.2020.110033_b0610","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.1983.03340150039023","article-title":"The use of imipramine in depressed patients with congestive heart failure","volume":"250","author":"Glassman","year":"1983","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0615","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpt.128","article-title":"Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window","volume":"98","author":"Coutant","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0620","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0625","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","article-title":"Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis","volume":"56","author":"Lee","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mehy.2020.110033_b0630","article-title":"Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-lnterleukin-6 monoclonal antibody (Sirukumab) and cytochrome P450 activities in a phase I study in patients with rheumatoid arthritis using a cocktail approach","author":"Zhuang","year":"201555","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0635","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0640","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1208\/s12248-016-9890-5","article-title":"Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein-drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6","volume":"18","author":"Jiang","year":"2016","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.mehy.2020.110033_b0645","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/psp4.12003","article-title":"Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity","volume":"4","author":"Xu","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"10.1016\/j.mehy.2020.110033_b0650","unstructured":"Summary on compassionate use of Remdesivir Gilead [Internet]. European Medicines Agency. 2020 [cited May 5, 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use-remdesivir-gilead_en.pdf."},{"issue":"1","key":"10.1016\/j.mehy.2020.110033_b0655","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.mehy.2020.110033_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.hjc.2020.03.002","article-title":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design","author":"Deftereos","year":"2020","journal-title":"Hellenic J Cardiol"},{"issue":"6","key":"10.1016\/j.mehy.2020.110033_b0665","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.mehy.2020.110033_b0670","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine-Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mehy.2020.110033_b0675","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4031","article-title":"Critical care utilization for the COVID-19 outbreak in lombardy, italy: early experience and forecast during an emergency response","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110033_b0680","unstructured":"Murray CJL. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. medRxiv. 2020:2020.03.27.20043752. 10.1101\/2020.03.27.20043752."},{"issue":"2","key":"10.1016\/j.mehy.2020.110033_b0685","article-title":"Drug-associated disease: cytochrome P450 interactions","volume":"22","author":"Mann","year":"2006","journal-title":"Crit CareClin."},{"key":"10.1016\/j.mehy.2020.110033_b0690","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mehy.2020.110033_b0695","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1440-1681.12081","article-title":"Clinical implications from drug-drug and drug-disease interactions in older people","volume":"40","author":"Gnjidic","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"10.1016\/j.mehy.2020.110033_b0700","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: a narrative review","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expert Opin Drug Saf"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:29:59Z","timestamp":1759692599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720311750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":140,"alternative-id":["S0306987720311750"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110033","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110033"}}